Compare Davita Inc (DVA) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Oklo Inc — how do they compare? Davita Inc trades at $232 (market cap $14.92B), while Oklo Inc trades at $46.44 (market cap $8.05B). The key difference: Davita Inc is the larger of the two by market cap, and Davita Inc is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.
| DVA | OKLO | |
|---|---|---|
Market Cap | $14.92B | $8.05B |
Sector | Health | Technology |
52-Week High | $235.71 | $174.14 |
52-Week Low | $103.87 | $45.58 |
Enterprise Value | $27.47B | $5.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
OKLO stock trades at $45.81, down 6.22% in the last session, reflecting ongoing volatility. The company shows strong analyst support with 77% buy ratings and a $90.88 consensus price target, but faces fundamental challenges with negative ROE (-8.87%) and net income (-$105.66M). Recent DOE approval for the Groves Isotope Test Reactor represents a key regulatory milestone, though cash flow remains heavily dependent on financing activities.
The outlook balances significant growth potential in nuclear energy against substantial execution risks. While analyst targets suggest 98% upside, the company must navigate regulatory hurdles and achieve profitability amid negative earnings trends. The stock's bearish technical signals and high valuation multiples require careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
